Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine
2024年7月10日 - 2:30PM
- Key contribution to the
acceleration of the development of ZENEO® Epinephrine
- Financial support includes mainly
grants, as well as subsidized loans
- France 2030 Plan dedicated to
supporting French companies demonstrating outstanding growth and
innovation potential
Dijon, France, July
10th, 2024 07:30 CET -- Crossject
(ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in
advanced phases of development and registration for
ZEPIZURE®, its emergency treatment for the
management of epileptic crises based on its award-winning
needle-free auto-injector ZENEO®, announces that
it has been awarded €6.9 million in public funding as part of the
"i-Démo" call for projects under the France 2030 Plan, operated by
Bpifrance on behalf of the French Government.
The France 2030 plan aims at supporting French
companies that demonstrate exceptional potential for growth and
innovation. It will support Crossject's innovative project to
accelerate the development of its ZENEO® Epinephrine1 needle-free
autoinjector, and save lives thanks to this new emergency treatment
administered by a patient or its family in the event of severe
allergic reactions (anaphylactic shock).
The project, which runs until 2026, consists of
subsidies for 60% of the total, and of subsidized loans for the
remainder, with an initial payment of 1.7 million euros scheduled
in the coming weeks, a development milestone of 4 million euros
expected in August 2025 and the balance at the end of the project
in 2026. The product is expected to generate cumulative sales of
around 1 billion euros by 2032 for Crossject and its distributors,
contribute to the creation of more than 160 jobs over the period
2024-2032, and support Crossject's actions to reduce the carbon
footprint of ZENEO® Epinephrine. The project was also certified by
the French cluster PMT.
The drug solution in ZENEO® Epinephrine is
innovative and patented by Crossject (FR3095122B1, WO2020212381A1).
Importantly, it relies on a proprietary sulfite-free formulation.
Sulfites are used as preservatives in many current products and are
known to trigger intolerance, or even allergy, which can lead to an
anaphylactic shock, the very event that needs to be treated.
Moreover, Crossject’s new solution shows superior shelf-life
performance and should enable a longer stability period compared to
current drugs. The formulation developed by Crossject should hence
not only reassure patients about the risk of drug-related allergy,
but also meet their strong need for a simpler device that can be
kept for longer.
In addition, the ZENEO® auto-injector ensures a
simple, complete injection of the entire dose in just a few
milliseconds, with negligible residual volume. This should be a
significant advantage over needle-based systems on the market.
Patrick Alexandre, CEO of Crossject, declared:
« We are honoured to be supported by the France 2030
innovation Plan. It bears witness to the innovative nature of our
know-how and the impact that our innovations can have on
healthcare. I would like to thank the French Government for its
confidence, which reinforces the strategic dimension and promise of
our needle-free injection technology. This financing will enable us
to accelerate our research and development efforts to bring ZENEO
Epinephrine® to market and save lives in the field of anaphylactic
shock. »
Crossject plans to file marketing authorization
applications for ZENEO® Epinephrine in 2026 with regulatory
authorities in Europe and the United States.
Virginie Fontaine, Head of Healthcare Innovation
at Bpifrance, added: « We are delighted to support Crossject's
ZENEO® Epinephrine development project, derived from its unique
expertise in needle-free injections. This high-quality clinical
program brings together recognized national players and jointly
answerss a strong medical need and an issue of industrial
sovereignty. This innovation in the field of emergency treatments
is fully in line with the French Government's healthcare
priorities. »
About Crossject
Crossject SA (Euronext:
ALCJ; www.crossject.com) is an emerging specialty
pharmaceutical company developing medicines for emergency
situations harnessing its award-winning needle-free auto-injector
ZENEO® platform. Crossject is in advanced regulatory development
for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60
million contract* with the U.S. Biomedical Advanced Research and
Development Authority (BARDA). The Company’s versatile ZENEO®
platform is designed to enable patients or untrained caregivers to
easily and instantly deliver a broad range of emergency drugs via
intramuscular injection on bare skin or even through clothing. The
Company’s other products in development include mainly solutions
for allergic shocks and adrenal insufficiencies, as well as
therapies and other emergency indications.
* Contract no: 75A50122C00031 with the
Department of Health and Human Services; Administration for
Strategic Preparedness and Response; Biomedical Research and
Development Authority
About the France 2030 Investment
Plan
- A
double ambition: to transform key sectors of our economy
(healthcare, energy, automotive, aeronautics and space) over the
long term through technological innovation, and to position France
not just as a player, but as a leader in tomorrow’s world. From
fundamental research, to the emergence of an idea, up to the
production of a new product or service, France 2030 supports the
entire life cycle of innovation from its inception right through to
industrialization.
- An
unprecedented commitment: 54 billion euros will be
invested so that our companies, universities and research
organizations can make successful transitions to these strategic
sectors. The aim is to enable them to respond competitively to the
ecological and attractiveness challenges of the coming world, and
to create the future leaders of our sectors of excellence. France
2030 is defined by two cross-functional objectives: to devote 50%
of its spending to decarbonizing the economy, and 50% to emerging,
innovative players, without spending money that is detrimental to
the environment (« Do No Significant Harm »).
- A
collaborative implementation: it is designed and deployed
in consultation with economic, academic, local and European
players, to determine its strategic orientations and flagship
actions. Project leaders are invited to submit their applications
via open, demanding and selective procedures, in order to benefit
from government support.
- Managed by the
« Secrétariat général pour l’investissement » on
behalf of the Prime Minister and implemented by the « Agence
de la transition écologique (ADEME) » and the « Agence
nationale de la recherche (ANR) », by Bpifrance, and by the
Caisse des Dépôts et Consignations (CDC).
About Bpifrance
Bpifrance finances French companies - at every stage of their
development - with credit, loan guarantees and equity capital.
Bpifrance supports them in their innovation and international
projects. Bpifrance now also covers their export activities through
a wide range of products. Consulting, university, networking and
acceleration programs for startups, SMEs and Mid-caps are also part
of the offer available to entrepreneurs from Bpifrance. Thanks to
Bpifrance and its 50 regional offices, entrepreneurs benefit from a
single, close and efficient contact to help them meet their
challenges.
For further information, please contact:
Investisseurs Natasha DrapeauCohesion Bureau+41 76
823 75 27natasha.drapeau@cohesionbureau.com |
Média Sophie BaumontCohesion Bureau+33 6 27 74 74
49sophie.baumont@cohesionbureau.com |
1 Epinephrine is known as adrénaline in Europe.
Crossject (EU:ALCJ)
過去 株価チャート
から 9 2024 まで 10 2024
Crossject (EU:ALCJ)
過去 株価チャート
から 10 2023 まで 10 2024